Upsher-Smith in up to $232M PRXI deal

7 September 2008

Minnesota, USA-based Upsher-Smith has entered into a worldwide licensing deal with Proximagen Neuroscience under which it will acquire the UK firm's PRXI program, now at the preclinical stage, for the symptomatic treatment of Parkinson's disease.

Under the terms of the accord, U-S will make upfront and milestone payments to Proximagen totaling up to $232.0 million. The company will also make an investment of $6.0 million, at 200 pence per share, to acquire a 7.1% stake in the UK firm - a 100% premium.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight